Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance.

Alimentary pharmacology & therapeutics·2026
Same author

Efficacy of linaclotide in irritable bowel syndrome with constipation: Real-world data.

Neurogastroenterology and motility·2018
Same author

Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation?

Alimentary pharmacology & therapeutics·2017
Same author

Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts? Authors' reply.

Alimentary pharmacology & therapeutics·2017
Same author

Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic.

Neurogastroenterology and motility·2017
Same author

Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin.

Alimentary pharmacology & therapeutics·2017

Related Experiment Video

Updated: May 21, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Evidence-based management of ulcerative colitis.

D J Gracie1, A C Ford

  • 1Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.

Minerva Gastroenterologica E Dietologica
|May 31, 2012
PubMed
Summary

Ulcerative colitis (UC) management focuses on achieving remission and preventing relapse. Effective treatments include 5-aminosalicylic acid (5-ASA) at doses over 2g/day for mild to moderate flares and maintenance therapy.

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Related Experiment Videos

Last Updated: May 21, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Inflammatory Bowel Disease

Background:

  • Ulcerative colitis (UC) is a chronic gastrointestinal inflammatory disorder with unknown etiology and a prevalence of 0.25%.
  • UC significantly impacts healthcare costs and patient quality of life due to its relapsing-remitting nature.
  • Current medical therapies aim to minimize disease relapses and reduce reliance on glucocorticosteroids.

Purpose of the Study:

  • To review current therapeutic strategies for ulcerative colitis (UC).
  • To evaluate the efficacy of various treatments for inducing remission and preventing relapse in UC patients.
  • To discuss management options for chronic, difficult-to-treat UC.

Main Methods:

  • Literature review of existing studies on UC treatment efficacy.
  • Analysis of data regarding drug dosages and their impact on remission and relapse rates.
  • Consideration of surgical and novel therapeutic interventions.

Main Results:

  • Oral or topical 5-aminosalicylic acid (5-ASA), alone or combined, are more effective than placebo for inducing remission in mild to moderate UC flares.
  • Doses of oral 5-ASA exceeding 2g/day are associated with a higher likelihood of successful remission.
  • 5-ASA (at >2g/day) and azathioprine are effective in preventing UC relapse once remission is achieved.
  • Glucocorticosteroids, infliximab, and cyclosporine are effective for acute severe UC.
  • Granulocyte/monocyte adsorptive apheresis shows potential but requires further validation in Western populations.

Conclusions:

  • 5-ASA, particularly at doses over 2g/day, is a cornerstone for both induction and maintenance therapy in mild to moderate UC.
  • For severe UC flares, established treatments like glucocorticosteroids, infliximab, and cyclosporine remain crucial.
  • Colectomy with ileal pouch anal anastomosis is an option for refractory cases, while novel therapies like apheresis need more research for broader application.